| Literature DB >> 29657982 |
Darren Shu Jeng Ting1, Sathish Srinivasan2,3, Jean-Pierre Danjoux1.
Abstract
The number of laser in situ keratomileusis (LASIK) procedures is continuing to rise. Since its first application for correcting simple refractive errors over 25 years ago, the role of LASIK has extended to treat other conditions, including postkeratoplasty astigmatism/ametropia, postcataract surgery refractive error and presbyopia, among others. The long-term effectiveness, predictability and safety have been well established by many large studies. However, due to the creation of a potential interface between the flap and the underlying stroma, interface complications such as infectious keratitis, diffuse lamellar keratitis and epithelial ingrowth may occur. Post-LASIK epithelial ingrowth (PLEI) is an uncommon complication that usually arises during the early postoperative period. The reported incidence of PLEI ranged from 0%-3.9% in primary treatment to 10%-20% in retreatment cases. It can cause a wide spectrum of clinical presentations, ranging from asymptomatic interface changes to severe visual impairment and flap melt requiring keratoplasty. PLEI can usually be treated with mechanical debridement of the affected interface; however, additional interventions, such as alcohol, mitomycin C, fibrin glue, ocular hydrogel sealant, neodymium:yttriumaluminum garnet laser and amniotic membrane graft, may be required for recurrent or refractory cases. The aims of this review are to determine the prevalence and risk factors of PLEI; to describe its pathogenesis and clinical features and to summarise the therapeutic armamentarium and the visual outcome of PLEI.Entities:
Keywords: cornea; ocular surface; treatment lasers; treatment surgery
Year: 2018 PMID: 29657982 PMCID: PMC5895975 DOI: 10.1136/bmjophth-2017-000133
Source DB: PubMed Journal: BMJ Open Ophthalmol ISSN: 2397-3269
Probst/Machat classification of epithelial ingrowth (adapted and modified from Neff and Probst)39
| Grade | Signs | Progressive | Location | Management |
| 1 | Thin growth, 1–2 cells thick, non-progressive, difficult to detect, well-delineated white line along advancing edge, no flap change | No | 2 mm within flap edge | No treatment required |
| 2 | Thicker growth, discrete cells within epithelial nest, no demarcation line along nest, easily detectable on slit lamp, rolled or grey flap edge with no melt | Usually (but slowly) | 2 mm within flap edge | Non-urgent treatment within 2–3 weeks |
| 3 | Pronounced growth, several cells thick, opaque ingrowth, geographic areas of necrotic cells with no demarcation line, flap rolled with thickened whitish-grey appearance, peripheral confluent haze at flap edge | Yes | >2 mm from flap edge | Urgent treatment |
| 4 | Aggressive growth, strands of epithelial cells invading towards visual axis, may result in flap melt | Yes | Threatening/affecting visual axis | Urgent treatment |
Figure 1(A) Slit lamp photography showing an area of epithelial nest/ingrowth at the flap-stromal interface (red, up arrow) associated with a dislocated, infolded superior temporal LASIK flap (blue, left arrows). (B) Slit lamp photography showing diffuse opaque epithelial ingrowth (red, left arrows) associated with occult traumatic dislocation of LASIK flap. (C) Slit lamp photography showing an apparently clear cornea after removal of epithelial ingrowth. (D) However, subtle residual epithelial ingrowth (yellow, up arrows) was identified on anterior segment optical coherence tomography (AS-OCT). At 3-month postremoval of epithelial ingrowth, there was a recurrence of epithelial ingrowth (visible on slit lamp examination) at the same area highlighted by the AS-OCT.
The summary of visual outcomes, recurrence rate and complications of various treatment modalities for postlaser in situ keratomileusis (LASIK) epithelial ingrowth
| Treatment | Study (year) | No. of eyes | Visual outcomes | R* | F/U, months (SD) | Complications |
| MD only | Wang and Maloney (2000) | 43 | 91% retained CDVA postoperatively | 23% | – | None |
| Rapuano† (2010) | 4 | CDVA=100%≥ 6/12; 25%≥ 6/7.5 | 0% | 16.5 (18.9) | None | |
| Henry | 45 | UDVA=53%≥ 6/7.5; CDVA=78%≥ 6/7.5 | 36% | 12 | None | |
| MD+diluted ethanol | Anderson and Hardten‡ (2003) | 3 | – | 100% | 5 | None |
| MD+50% ethanol | Haw and Manche (2001) | 4 | CDVA=100%≥ 6/7.5 | 0% | 3 | 2 DLK, resolved with topical CS |
| MD+70% isopropyl alcohol | Lahners | 22 | – | 36% | - | None |
| MD+ocular hydrogel sealant | Ramsook and Hersh (2015) | 2 | CDVA=100%≥ 6/9 | 0% | 1.5 | None |
| Yesilirmak | 1 | CDVA=6/6 | 0% | 6 | None | |
| MD+FG | Anderson and Hardte‡ (2003) | 3 | CDVA=100%≥ 6/6 | 0% | 5 | None |
| Yeh | 1 | UDVA=6/21 | 0% | 20 | None | |
| Hardten | 39 | UDVA=74%≥ 6/12; CDVA=85% ≥ 6/7.5 | 7.70% | 26.6 (17.0) | None | |
| MD+FG+70% ethanol+ | Wilde | 4 | CDVA=100≥ 6/9 | 0% | 11.8 | None |
| MD+FS | Rojas | 20 | UDVA=45%≥ 6/6, 80%≥ 6/12 | 0% | 10.5 (14.3) | None |
| Rapuano† (2010) | 9 | UDVA=67%≥ 6/12;CDVA=67%≥ 6/12 | 22% | 16.5 (18.9) | 1 mild flap necrosis | |
| Güell | 13 | Mean UDVA=6/7.5 | 0% | 12 | None | |
| MD+FS+proparacaine | Spanggord | 6 | CDVA=67%≥ 6/12 | 33% | 12 | None |
| MD+FS+FG | Narváez | 1 | CDVA=6/6 | 0% | 15 | None |
| MD+AMG±FS±ethanol | Lee | 1 | CDVA=6/9 | 0% | 7 | None |
| Azar | 1 | UDVA=6/7.5 | 0% | 6 | None | |
| Kwon | 1 | CDVA=6/6 | 0% | 5 | None | |
| MD+PTK | Fagerholm | 5 | CDVA=100%≥ 6/12 | 20% | – | None |
| MD+PTK+AMG | Lee | 1 | UDVA=6/6 | 0% | 4 | None |
| Nd:YAG laser | Ayala | 30 | 80% disappearance of PLEI | 0% | 24 | None |
| Lindfield | CDVA=100%≥ 6/5 | 0% | 12 | None | ||
| Kim | 2 | UDVA=6/6 | 0% | 9 | None |
The majority of studies that specifically evaluated the treatment outcome of significant post-LASIK epithelial ingrowth (PLEI) are included in this table.
*Recurrence refers to rate of significant recurrence of epithelial ingrowth following the initial treatment.
†Rapuano reported 13 eyes of PLEI that underwent mechanical debridement, with 9 eyes being treated with additional flap suturing.
‡This study included three patients who were all initially treated with MD and diluted ethanol. However, all of them had a significant recurrence of epithelial ingrowth which required a further MD and application of fibrin glue.
AMG, amniotic membrane graft; CDVA, corrected distance visual acuity; CS, corticosteroids; DLK, diffuse lamellar keratitis; FG, fibrin glue; FS, flap suturing; MD, mechanical debridement; MMC, mitomycin C; Nd:YAG, neodymium: yttrium aluminum garnet; PTK, phototherapeutic keratectomy; UDVA, uncorrected distance visual acuity.